Israel's DreaMed gets FDA clearance for diabetes solution

• Published date: 06 October 2021
• Author: ZEV STUB
• Publication title: Jerusalem Post, The: Web Edition Articles (Israel)

The company's Advisor Pro is the first decision support system that has been cleared to assist healthcare providers in the management of diabetes patients who use insulin pumps or injections and monitor their glucose using continuous glucose monitor and/or blood glucose meters.

"There are simply not enough endocrinologists to provide the expert level of care that all people with diabetes require continuously," said Eran Atlas, DreaMed's Founder & CEO. "In the US alone, there are over 41,000 adults per endocrinologist which results in more than 50% of all people with diabetes that are not well managed due to limited access to proper care. "DreaMed empowers the medical staff to treat significantly more patients by providing access to expert endocrinological advice in primary care settings. "We can potentially help avoid thousands of unnecessary hospitalizations and medical complications for the community of people with diabetes and change the overall standards of care in this sector. The FDA clearance puts us on a path to help millions of people with diabetes and our next step is to develop and extend our solution to cover all injectable or oral medications for diabetes."

cnxps.cmd.push(function () { cnxps({ playerId: '36af7c51-0caf-4741-9824-2c941fc6c17b'...